TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT07436728: A Phase 1/2 First-in-Human, Open-Label, Dose Escalation and Expansion Trial of TAK-505 Monotherapy in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

Sponsor: Takeda · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 151 pts

Competing Trials Overlap

9 Active Trials

Excess Burn Exposure

$8,443,050

Rescue Site Savings

+$5,576,340

Unlock Full NCT07436728 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07436728 Rescue Dossier →